Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

NCT03775265 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03775265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03775265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 3, 2019
Completion date
June 1, 2027
Enrollment
475 (estimated)
Sites
365

Conditions

As the registry lists them; a condition with its own page is linked.

bladder urothelial carcinoma, muscle invasive bladder carcinoma, stage ii bladder cancer ajcc v8, stage iiia bladder cancer ajcc v8